Allergy & Immunology
A Comprehensive Review on the Antimicrobial Activities and Structure-Activity Relationships (SARs) of Rhodanine Analogues
Rhodanines are five-member heterocyclics having sulfur nitrogen and oxygen atoms in their ring structure and exhibit potent as well as a broad range of pharmacological activities. They are thiazolidine derivatives and are well-known in medicinal chemistry for their wide spectrum of antimicrobial activities. Various modifications can be made to the structure of the rhodanine ring. Studies in recent years have validated the possibility of the potential of rhodanine derivatives to exhibit antimicrobial activity against both Gram-positive and Gram-negative bacterial strains as well as mycobacterial and fungal strains. In this review the synthesis biological activity and Structure-activity Relationships (SARs) of molecules based on rhodanine against different microbes have been described
Assessment of Interleukin 17 in Egyptian Systemic Lupus Erythematosus Patients as a Biomarker in Disease Activity
Introduction: Systemic lupus erythematosus (SLE) is a chronic idiopathic systemic autoimmune disorder with dysregulation of adaptive and innate immune systems. Interleukin (IL)-17 is the prototypical pro-inflammatory cytokine of T helper 17 (Th17) cells. Therefore it contributes to the pathogenesis of human SLE. Aim: The aim of the research paper was the evaluation of IL-17 level as a biomarker in the SLE cohort and its relation to disease activity and analysis of IL-17 concentration in patients with lupus nephritis and non-lupus nephritis. Methods: The research enrolled 45 SLE patients according to Systemic Lupus International Collaborating Clinics Classification Criteria (SLICC) and age and sex-matched. The patients underwent full history clinical examination laboratory investigation and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) calculation. Results: The mean age ± SD of the participants equaled 32 ± 11 years and serum IL-17 in SLE cases was statistically significantly high (p < 0.001). No statistically significant correlations were reported between disease activity according to SLEDAI and IL-17. In addition a statistically significant positive correlation was reported between IL-17 and ESR and a high statistically significant negative correlation was reported between IL-17 and C3 and C4 (P < 0.001). A statistically significant positive correlation was reported between IL-17 and 24-hour urinary proteins with a Pvalue of 0.01. Conclusion: SLE cases demonstrated higher levels of serum IL-17 contributing to SLE pathogenesis. However no statistically significant difference was reported between IL-17 and Lupus nephritis. IL-17 and SLE activity (SLEDAI) did not correlate. A statistically significant positive relation was reported between IL-17 and 24-hour urinary proteins. Additionally a high statistically significant negative correlation was reported between IL-17 and C3 and C4.
Hypoparathyroidism: Musculoskeletal Manifestations Related to Parathormone Deficiency
Background: Hypoparathyroidism is a rare metabolic disorder that can be responsible for musculoskeletal manifestations. Aim: We present a systematic review of musculoskeletal manifestations of adult-onset nonsurgical nongenetic hypoparathyroidism. Methods: A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline using the MEDLINE database including manuscripts describing musculoskeletal manifestations of adult-onset nonsurgical nongenetic hypoparathyroidism. Results: Musculoskeletal manifestations included myopathy shoulder disorder immune-negative non-erosive peripheral arthritis axial involvement simulating spondylarthritis and diffuse ligamentous ossifications. An association between hypoparathyroidism and spondyloarthritis or autoimmune diseases is possible. T-cell activation seen in patients with hypoparathyroidism may explain the co-occurrence of hypoparathyroidism with other autoimmune diseases. The treatment of these manifestations is based on calcium and active vitamin D supplementation. Parathyroid hormone may have an anabolic effect on muscle atrophy and muscle weakness. Parathyroid hormone can also promote bone formation and bone resorption by stimulating osteoclast differentiation by increasing RANKL (receptor activator for nuclear factor kappa-B ligand) expression. Therefore hypoparathyroidism can be responsible for an increase in bone mineral density. However the risk of fractures does not appear to be reduced due to changes in bone microarchitecture and the high risk of falls. Treatment with parathyroid hormone has been shown to improve bone microarchitecture. Conclusion: Our review showed that musculoskeletal manifestations are frequent in patients with hypoparathyroidism including muscular axial peripheral articular and entheseal manifestations.
Low Frequency of Upper Gastrointestinal Bleeding Despite Non-Steroidal Anti-Inflammatory Drugs and Corticosteroids in Patients with Rheumatoid Arthritis
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease. It has been identified that non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids can be essential risk factors for developing complications such as upper gastrointestinal bleeding (UGIB). Objective: This study aimed to describe the safety profile of drugs used to treat RA focused in UGIB. Methods: A cross-sectional study of patients with RA between 2015 and 2021 a description of the population and an evaluation of the relationship with UGIB through bivariate analysis and logistic regression. Results: Of 405 individuals 16 presented UGIB (93.8% women mean age was 65±13.6 years). No statistically significant differences were found regarding UGIB and medication use except for the mean dose of corticosteroids. In the multivariate analysis it was found that the presence of anemia in the last three months had an adjusted OR (AOR) of 16.1 (95% CI 2.74- 24.23) and higher HAQ values during the previous three months had an AOR of 6.17 (95% CI 1.79- 21.24). Conclusion: This study found a low frequency of UGIB in patients with RA. More significant disability and anemia in the previous months were independently associated with UGIB. The low frequency of NSAID use in this population is noteworthy. In general reasonable medication use related to this complication is recommended.
Exploring the Promising Role of Guggulipid in Rheumatoid Arthritis Management: An In-depth Analysis
Background: Guggulipid an oleo-gum resin extracted from the bark of Commiphora wightii of the Burseraceae family holds a significant place in Ayurvedic medicine due to its historical use in treating various disorders including inflammation gout rheumatism obesity and lipid metabolism imbalances. Objective: This comprehensive review aims to elucidate the molecular targets of guggulipids and explore their cellular responses. Furthermore it summarizes the findings from in-vitro in-vivo and clinical investigations related to arthritis and various inflammatory conditions. Methods: A comprehensive survey encompassing in-vitro in-vivo and clinical studies has been conducted to explore the therapeutic capacity of guggulipid in the management of rheumatoid arthritis. Various molecular pathways such as cyclooxygenase-2 (COX-2) vascular endothelial growth factor (VEGF) PI3-kinase/AKT JAK/STAT nitric oxide synthase (iNOS) and NFΚB signaling pathways have been targeted to assess the antiarthritic and anti-inflammatory effects of this compound. Results: The research findings reveal that guggulipid demonstrates notable antiarthritic and anti-inflammatory effects by targeting key molecular pathways involved in inflammatory responses. These pathways include COX-2 VEGF PI3-kinase/AKT JAK/STAT iNOS and NFΚB signaling pathways. in-vitro in-vivo and clinical studies collectively support the therapeutic potential of guggulipid in managing rheumatoid arthritis and related inflammatory conditions. Conclusion: This review provides a deeper understanding of the therapeutic mechanisms and potential of guggulipid in the management of rheumatoid arthritis. The collective evidence strongly supports the promising role of guggulipid as a therapeutic agent encouraging further research and development in guggulipid-based treatments for these conditions.
Reaction Time in Fibromyalgia Patients
Background: Fibromyalgia has unknown aetiology and is associated with reduced information processing speed and therefore prolonged reaction time. However the processes underlying this are unknown. Objectives: First to compare the reaction time in a cohort of fibromyalgia patients and a matched group of normal controls. Second to assess whether detailed symptoms of pain and autonomic function as well as measures of tinnitus fatigue daytime sleepiness and Mycoplasma pneumoniae infection are predictors of reaction time in fibromyalgia. Methods: The between-groups mean serial five-choice reaction time difference was assessed in a cohort of fibromyalgia patients and in a matched group of normal controls in an analytical casecontrolled study. With the mean serial five-choice reaction time as the dependent variable for the fibromyalgia group a mixed stepwise multiple linear regression was performed with inputs relating to pain dysautonomia tinnitus fatigue daytime sleepiness and Mycoplasma pneumoniae infection. Results: The mean (standard error) serial five-choice reaction time for the fibromyalgia group was 448.4 (23.0) ms compared with 386.3 (8.3) ms for the control group (p = 0.007). The final multiple linear regression model (p < 0.001; adjusted R2 = 0.772) contained 13 predictors: eight sensory pain and three affective pain parameters and Mycoplasma pneumoniae IgG and IgA assay results. Conclusion: Certain sensory and affective pain parameters as well as Mycoplasma pneumoniae infection appear to be predictors of reaction time in fibromyalgia. Further research into the pathophysiological mechanisms by which they affect information processing is warranted and may shed light on the aetiology of fibromyalgia.
Severe Acro-osteolysis Mimicking Arthritis Mutilans in a Patient with Primary Hyperparathyroidism: A Case Report
Background: Primary hyperparathyroidism (PHPT) should be considered in the differential diagnosis of a patient with suspected secondary osteoporosis and severe osteoporosis with multiple fractures is frequently the first clinical manifestation of the disease. Case Presentation: Mutilating arthritis (arthritis mutilans) can be part of the clinical presentation of a number of rheumatic diseases most commonly seen in psoriatic arthritis rheumatoid arthritis and juvenile idiopathic arthritis but also in systemic lupus systemic sclerosis and multicentric reticulohistiocytosis. Evidence exists that subperiosteal and subchondral bone resorption seen in PHPT could induce the so-called ‘osteogenic synovitis’ which could eventually lead to the development of a secondary osteoarthritis with bone deformities. Conclusion: Here we present a case report of a patient initially diagnosed with PHPT who presented with mutilating arthritis of the finger joints and discuss whether the severe acro-osteolysis is a manifestation of the endocrinopathy or whether there is a co-existing undiagnosed inflammatory joint disease.
Insight into the Epidemiology of the Adult-onset Systemic Autoimmune Rheumatic Diseases in Egypt: A Descriptive Study of 8690 Patients
Background/Objective: Although systemic autoimmune rheumatic diseases (SARDs) seem to be ubiquitous Africa and the Middle East seem to be a remarkable exception with scarcity of data compared with the developed countries. Furthermore most of the studies addressed a particular disease. This work aimed to shed light on the relative frequency and epidemiology of the different adult-onset SARDs in Egypt. Methods: This is a retrospective hospital-based study including six university hospitals providing free health care services: Cairo Alexandria Tanta Suez Canal Beni-Suef and Assiut University Hospitals. All available files for patients attending the outpatient clinics or admitted to the inpatient departments between January 2000 and December 2021 were retrospectively reviewed. Data about the patient’s diagnosis gender age at disease onset year of disease onset and residence were collected. Results: The study included 8690 patients. Rheumatoid arthritis (RA) systemic lupus erythematosus (SLE) Behçet’s disease (BD) and spondyloarthropathies (SPA) represented the main SARDs in Egypt. They mainly affect young patients below the age of 40 years. RA and SLE mainly affect females; males are mainly affected by axial SPA and BD. There is an increasing incidence of SARDs during the study period. Conclusion: The study revealed the high burden of SARDs in Egypt helping better allocation of economic resources for the management of diseases of the highest prevalence and those affecting the young reproductive age groups. Increased public and medical staff awareness about SARDs is recommended to help early referral of patients to rheumatologists and hence better estimation of their epidemiology.
Study on the Expression and Potential Function of LncRNA in Peripheral Blood of Patients with Ankylosing Spondylitis
Background: Ankylosing spondylitis (AS) is an autoimmune disease that has the characteristics of difficult early diagnosis and a high disability rate. Objective: The objective of this study was to further explore the possible mechanism and potential function of lncRNA in AS. Methods: We used lncRNA microarray technology to detect the expression of lncRNA and mRNA in patients with active AS stable patients and healthy controls (HC). Afterward bioinformatics analysis was conducted on differentially expressed genes. Seven differentially expressed lncRNAs were screened out for real-time fluorescent quantitative PCR (RT-qPCR) combined with various clinical indicators for correlation analysis and the receiver operating characteristic (ROC) curve was used to analyze the potential of lncRNA as a diagnostic marker for AS. Results: The results showed that the expression levels of NR-037662 and ENST00000599316 in the AS subgroups were significantly higher than those in the HC group while the expression levels of ENST00000577914 and ENST00000579003 were lower than those in the HC group. The expression levels of NR-003542 and ENST00000512051 in the ASA group were significantly higher than those in the ASS and HC groups while NR-026756 was just the opposite. Spearman’s correlation analysis showed that the expression level of NR-003542 was positively correlated with Bath Ankylosing Spondylitis Functional Index (BASFI) Erythrocyte Sedimentation Rate (ESR) and high sensitivity C-Reactive Protein (hsCRP). The expression level of NR-026756 was negatively correlated with the Bath Ankylosing Spine Inflammatory Disease Activity Index (BASDAI) BASFI ESR hsCRP and globulin (GLOB). In addition it was also found that the ROC curve analysis of the 4 lncRNAs between the AS group (ASA group and ASS group) and the HC group were statistically significant and the area under the curve (AUC) of NR-037662 ENST00000599316 ENST00000577914 and ENST00000579003 was 0.804 0.812 0.706 and 0.698 respectively. Conclusion: It was found that these differentially expressed lncRNAs of AS may be involved in the occurrence and development of the disease. Among them NR-037662 ENST00000599316 ENST00000577914 and ENST00000579003 might have the potential to become AS diagnostic molecular markers. Moreover NR -003542 ENST00000512051 and NR-026756 might have the potential to be indicators of disease activity.
An Overview of Adalimumab Therapy for Ankylosing Spondylitis
Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease known for causing pain stiffness and reduced mobility in the axial skeleton. Adalimumab a tumor necrosis factor (TNF) inhibitor has emerged as a promising therapeutic option for AS. Methods: This systematic review involved a comprehensive search of randomized controlled trials related to AS treatment conducted in major databases such as MEDLINE Google Scholar and PubMed. The search terms encompassed ankylosing spondylitis adalimumab methotrexate other non-biologic DMARDs glucocorticoids NSAIDs and analgesics. A total of 14 randomized controlled trials with 4500 participants were included in the review. Results: The review's results revealed that adalimumab demonstrated notable superiority when compared to a placebo. It effectively reduced disease activity improved physical function and lowered inflammatory markers such as C-reactive protein and erythrocyte sedimentation rate. Adalimumab demonstrated a favorable safety profile with adverse events comparable to those observed with placebo. Conclusion: Based on the results adalimumab is deemed an effective treatment for AS showcasing its potential as a first-line therapeutic option. Notably no significant increase in adverse events was observed compared to placebo. However the conclusion emphasizes the need for further studies with extended follow-up durations to ascertain the long-term efficacy and safety of adalimumab in AS management. This systematic review provides valuable insights supporting the use of adalimumab in the treatment of AS and underscores the importance of ongoing investigations into its long-term effects to optimize its clinical utilization in AS patients.
Correlation between Quality of Life and Erythrocyte Sedimentation Rate with Disease Activity in Rheumatoid Arthritis
Background: Inflammatory markers are crucial in diagnosing and monitoring rheumatoid arthritis. Patients with rheumatoid arthritis (RA) live with constant pain that limits their daily activities. Our study highlights the effects of disease activity on the quality of life in patients with rheumatoid arthritis. Methods: Swollen joint count (SJC) tender joint count (TJC) and visual activity scale (VAS) were utilized to acquire patients' subjective feelings of wellness and their performance of routine daily activities to determine the disease activity. The patient's erythrocyte sedimentation rate (ESR) was measured at the clinical hematology laboratory using the Westergren method. The Quality of Life was rated on a scale of 1 to 10. Results: Our study found that disease activity is inversely proportional to the quality of life. Out of 111 patients 3 (2.7%) were in remission 1 (0.9%) had mild disease 51 (45.9%) had moderate disease and 56 (50.5%) had high disease activity. The ESR was normal (<20) in 11 patients (9.9%) moderately elevated (20-50) in 56 (50.5%) patients and very high (>50) in 44 (39.6%) patients. The study revealed that 66% of patients in remission had normal while 33% had moderately elevated ESR. 12.5% of patients with moderate disease activity had normal ESR and none with high disease activity had normal ESR. Of 44 patients with high ESR 7 had moderate disease activity and 37 had high disease activity. In our study 60% of patients had a less than 50% quality of life compared to patients with pre-arthritis. Conclusion: High disease activity affects the productivity and quality of life in patients with rheumatoid arthritis. Assessing the impact of different interventions on the QOL should be an essential task that can help define a holistic and integrative treatment and rehabilitation model for RA patients.
Mixed Connective Tissue Disease: The Two Cases Representing the Range of this Illness
Introduction: Mixed connective tissue disease (MCTD) is defined as a systemic rheumatic disease characterized by the presence of high titer anti-U1 ribonucleoprotein (U1 RNP) antibodies in combination with clinical features commonly seen in systemic lupus erythematosus (SLE) systemic sclerosis (SSc) rheumatoid arthritis (RA) and polymyositis (PM). Case Presentation: The annual incidence of MCTD is 1.9 per 100000 adults. Any organ system can be involved in MCTD however four clinical features that suggest the presence of MCTD rather than another systemic rheumatic disease are Raynaud phenomenon with swollen hands or puffy fingers absence of severe kidney disease and central nervous system (CNS) disease at first presentation generally insidious onset of pulmonary hypertension and presence of autoantibodies anti-U1 ribonucleoprotein (U1 RNP) especially antibodies to the 68 kD protein. MCTD although initially thought to be a disease with a benign course is not considered a valid argument at present. This connective tissue disorder can present with life-threating organ involvement with rapid progression of disease. Conclusion: We report two cases of MCTD one with mild disease and another with life-threatening illness describing the range of severity at presentation of this disorder.
Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients
Background: Curcumin-piperine might synergise with vitamin D to induce clinical remission in patients with systemic lupus erythematosus (SLE). Objective: To observe the improvement of patients with SLE clinically and the levels of inflammatory cytokines after receiving supplements of curcumin-piperine and cholecalciferol (Vitamin D3). Methods: Forty-five female SLE patients were included in a three-month double-blind randomized controlled trial. Participants were classified into: Group I (400 IU cholecalciferol + placebo three times daily n = 15) Group II (600 mg curcumin + 15800 m piperine once daily and three times daily placebo n = 15) and Group III (cholecalciferol 400 IU three times and 600 mg curcumin + 15800 mg piperine once a day n = 15). Mexican SLE disease activity score (Mex- SLEDAI) fatigue severity scale (FSS) TGF-β and IL-6 levels were measured from all patients before and after the treatments. Results: Mex-SLEDAI FSS and IL-6 were reduced significantly while TGF-β serum levels were increased in all groups after the treatments (p <0.05). Changes in Mex-SLEDAI score (p = 0.003 and p = 0.008) FSS (p = 0.001 and p <0.001) and TGF-β (p = 0.003 and p = 0.004) serum levels were significantly higher in group III compared to the group I or group II. On the other hand changes in Mex-SLEDAI FSS IL-6 and TGF-β serum levels were similar between groups I and II. Conclusion: Although vitamin D or curcumin-piperine alone could improve the clinical outcome and cytokines levels in SLE curcumin-piperine combined with vitamin D had the best outcome in improving the disease activity and cytokines levels among patients with SLE. (ClinicalTrials.gov number NCT05430087).
The Recommendation of the Mediterranean-styled Japanese Diet for Healthy Longevity
The Mediterranean diet listed as the intangible cultural heritage of humanity by UNESCO is known as healthy and consumed worldwide. The Japanese diet is also listed and considered healthy. This narrative review compares the Mediterranean diet with its Japanese counterpart. Research has reported that people in Mediterranean regions such as Italy and Greece have one-third of the mortality ratio from cardiovascular diseases compared to people in the United States and Northern Europe because of the difference in eating habits. Therefore Mediterranean diets are considered as healthy. A typical Western diet containing high amounts of fat sugar and calories is responsible for several diseases like metabolic syndrome and obesity which are induced by chronic inflammation. In contrast Mediterranean and Japanese diets contain them only less. The similarity between Mediterranean and Japanese diets is the substantial intake of vegetables beans and fish. On the other hand the Mediterranean diet consumes large amounts of olive oil especially polyphenol-rich extra virgin olive oil and dairy products but meat consumption is relatively small. In contrast the Japanese diet does not use oil and fat contains abundant fermented foods and consumes seaweed. Japan is known for its longevity and people think that a well-balanced diet daily is good for preventing and curing illness. In this regard finding non-disease conditions so-called “ME-BYO” and curing them before the manifestation of diseases is becoming more common. In this review we discuss the healthy eating habit “The Mediterranean-styled Japanese diet” which prevents ME-BYO condition and reduces the risk of various diseases. The Mediterranean-styled Japanese diet a hybrid of Mediterranean and Japanese diets reduces the risk of various diseases by suppressing chronic inflammation. This nutritional intervention prevents ME-BYO and is beneficial for healthy longevity. Hence a Mediterranean-styled Japanese diet might be helpful for healthy longevity in Japan and around the world.
Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity of Panax ginseng. A Scoping Review
Panax ginseng is one of the most important remedies in ancient Eastern medicine. In the modern Western world its reputation started to grow towards the end of the XIX century but the rather approximate understanding of action mechanisms did not provide sufficient information for an appropriate use. Nowadays Panax ginseng is frequently used in some pathological conditions but the comprehension of its potential beneficial effects is still incomplete. The purpose of this study is to highlight the most recent knowledge on mechanisms and effects of ginseng active ingredients on the intestinal microbiota. The human microbiota takes part in the immune and metabolic balance and serves as the most important regulator for the control of local pathogens. This delicate role requires a complex interaction and reflects the interconnection with the brain- and the liver-axes. Thus by exerting their beneficial effects through the intestinal microbiota the active ingredients of Panax ginseng (glycosides and their metabolites) might help to ameliorate both specific intestinal conditions as well as the whole organism's homeostasis.
Effects of Metformin Therapy on Thyroid Volume and Functions in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Single-center Prospective Study
Patients with impaired glucose metabolism have increased thyroid volume and a higher prevalence of nodules. Yet some studies show that there is an improvement in these thyroid parameters after diabetes treatment. Our observational study aimed to reveal the effect of treatment on thyroid function thyroid volume and the presence of nodules in newly diagnosed type 2 diabetes mellitus (T2DM) patients who were started on metformin treatment.
Euthyroid and subclinically hypothyroid patients with a serum TSH level of <10 mU/L who were newly diagnosed with T2DM and started on metformin as an antidiabetic treatment and not used any thyroid medication previously were included in our study. Patients' characteristics were recorded. Baseline and 6th-month serum thyroid function tests were scheduled. Baseline and 6th-month thyroid gland characteristics were examined by thyroid ultrasonography.
A total of 101 (37 males 64 females) newly diagnosed T2DM patients with euthyroid (n=95) or subclinical hypothyroidism (n=6) were included in the study. The mean age of the patients was 53.02 ± 11.9 years and the mean BMI was 29.60 ± 3.9 kg/m2. Fifty-two (52%) patients were classified as obese. Body weight BMI serum TSH ALT Anti-TPO levels and thyroid volume decreased significantly in the 6th-month compared to baseline values (p = 0.000; p = 0.000; p = 0.011; p = 0.022; p = 0.000 respectively). Serum anti-Tg fT4 fT3 levels and thyroid nodule count did not change significantly. A high agreement was found between the baseline and 6th-month nodule counts (gamma= 0.886; p < 0.001) and the presence of multi-nodularity in the thyroid (gamma= 0.941; p < 0.001) but no significant change was observed. Anti-TPO levels showed a significant decrease in both with and without obesity groups at the end of 6 months (p = 0.003 p = 0.009 respectively). Serum TSH level decreased significantly only in non-obese subjects (p = 0.004) and thyroid volume decreased significantly only in obese subjects (p = 0.000).
Our results suggest that metformin treatment significantly reduces body weight BMI thyroid volume and serum TSH ALT and Anti-TPO levels in patients with newly diagnosed T2DM. Moreover serum TSH levels showed a significant decrease in non-obese subjects while thyroid volume showed a significant decrease in obese subjects.
Healthy Diets and Lifestyles in the World: Mediterranean and Blue Zone People Live Longer. Special Focus on Gut Microbiota and Some Food Components
Longevity has been associated with healthy lifestyles including some dietary regimens such as the Mediterranean diet (MedDiet) and the Blue Zone (BZ) diets. MedDiet relies on a large consumption of fruit vegetables cereals and extra-virgin olive oil with less red meat and fat intake. Four major BZ have been recognized in the world namely Ogliastra in Sardinia (Italy) Ikaria (Greece) the Peninsula of Nicoya (Costa Rica) and Okinawa (Japan). Extreme longevity in these areas has been associated with correct lifestyles and dietary regimens. Fibers polyphenols beta-glucans and unsaturated fatty acids represent the major constituents of both MedDiet and BZ diets given their anti-inflammatory and antioxidant activities. Particularly inhibition of the NF-kB pathway with a reduced release of pro-inflammatory cytokines and induction of T regulatory cells with the production of the anti-inflammatory cytokine interleukin-10 are the main mechanisms that prevent or attenuate the “inflammaging.” Notably consistent physical activity intense social interactions and an optimistic attitude contribute to longevity in BZD areas. Commonalities and differences between MedDIet and BZ diets will be outlined with special reference to microbiota and food components which may contribute to longevity.
Comparing The Mediterranean and The Japanese Dietary Pattern in Relation to Longevity - A Narrative Review
The Mediterranean dietary pattern (MDP) and Japanese dietary pattern (JDP) have received increasing attention from the scientific community and media predominantly due to their association with increased longevity and health. Although similarities between the two dietary patterns are evident a detailed comparison between them is still relatively unexplored. This narrative review aimed to explore the similarities and differences between the MDP and JDP in terms of longevity while also reflecting on the adoption of these diets by other populations outside their regions of origin. Both dietary patterns are plant-based minimally processed and sustainable for their respective regions and have been shown to significantly prolong life expectancy in different populations. Nevertheless these dietary patterns also differ in terms of macronutrient ratios food preparation and consumption and individual cultural characteristics of each population. Additionally both dietary patterns are part of broader lifestyle patterns which include other behaviors such as abstaining from smoking engaging in regular physical activity having low stress levels and a sense of community spirituality/religiousness and purpose. The promotion of these two dietary patterns should be implemented in other regions after considering cultural and socio-economical characteristics.
Healthy Effects of Milk and Dairy Product Consumption in the Mediterranean Area and Japan
Milk is a food enriched in essential components for human health. Especially in the Mediterranean area besides cow’s milk milk from goats sheep and donkeys is largely used. The consumption of animal milk is an important component of the Mediterranean (MED) diet even if in moderate amounts. Milk is a complete food since it contains proteins carbohydrates and fats as well as micronutrients (minerals and vitamins). Milk-fermented products are largely consumed in the MED diet such as cheese and yogurt which are rich in essential metabolites bioactive compounds vitamins minerals and exopolysaccharides. A large body of evidence suggests that consumption of milk and dairy products does not increase the risk of all-cause mortality type 2 diabetes and cardiovascular disease even if some earlier studies have reported harmful effects associated with their higher consumption. Also in Japan despite the lower consumption of milk than in Western countries intake of bovine milk is associated with healthy effects. The present review describes the effects of the various constituents of animal milk on human health with special reference to the Mediterranean area and Japan. Experimental data and clinical trials support the ability of milk and dairy products to lower the risk of chronic diseases.